The key points are as follows:
This is an Indefinite Delivery Contract (IDC) awarded by the Department of Veterans Affairs (VA) National Acquisition Center to AstraZeneca Pharmaceuticals LP, a foreign-owned, for-profit pharmaceutical manufacturer. The contract is for the supply of acalabrutinib 100mg tablets, with a one-year base period and four one-year option periods, for a total ceiling value of $913,915,470.
The contract will procure the acalabrutinib tablets for use by the VA, Bureau of Prisons, and Indian Health Service. Offerors were required to provide pricing for ibrutinib 140mg capsules, acalabrutinib 100mg tablets, or zanubrutinib 80mg capsules, with the award going to the lowest cost option based on estimated annual requirements of 2,444 new patients. The awarded acalabrutinib product will be the sole Bruton Tyrosine Kinase (BTK) inhibitor listed on the relevant agency formularies, though current patients on other BTK inhibitors are not mandated to switch.
Generated 12/22/24, 12:03 AM